Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy
Efficacy of Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Pinar del Río, Cuba, 20200
- Diabetes Care Center. "Abel Santamaría Cuadrado" General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes with insulin therapy regimen of two daily doses.
- Signed informed consent.
Exclusion Criteria:
- Type 1 diabetes.
- Type 2 diabetes with glibenclamide treatment.
- Nephropathy or liver condition diagnosed by clinical and/or biochemical examination.
- Sepsis.
- Pregnancy.
- HbA1c values greater than 10%.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: B
Placebo
|
Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
|
|
Experimental: A
Diamel
|
Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference of insulin daily doses at week 24 and at the beginning of the study
Time Frame: 24 weeks
|
24 weeks
|
|
Difference of glucose concentrations (fasting and post-prandial) at week 24 and at the beginning of the study considering the adjusted insulin doses during treatment
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of hypoglycemic episodes during treatment
Time Frame: 24 weeks
|
24 weeks
|
|
Difference of HbA1c concentrations at week 24 and at the beginning of the study
Time Frame: 24 weeks
|
24 weeks
|
|
Difference of triglycerides and cholesterol concentrations at week 24 and at the beginning of the study
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Maria Elena de la Uz Herrera, MSC, "Abel Santamaría Cuadrado" General Hospital
- Study Director: Arturo Hernández Yero, PhD, National Institute of Endocrinology
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAT-0912-CU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.